Drug intelligence / Profile preview

SIT-033

Development stage: Unknown
Lead developer: Sitryx
Modality: Small Molecules
Administration: Oral

Overview

SIT-033 is a small molecule inhibitor of salt-inducible kinase 2 (SIK2), developed by Sitryx Therapeutics. It is designed to selectively target SIK2 isozymes, aiming to maximize efficacy and therapeutic index in the treatment of inflammatory bowel diseases such as ulcerative colitis. By inhibiting SIK2, SIT-033 modulates immune cell function and inflammation pathways implicated in chronic autoimmune and inflammatory diseases. The drug represents a novel mechanism among anti-inflammatory agents and remains in early-stage research[1][2][3][7].

Other names: SIT-033SIT033SIT 033

Targets

SIK2 (Salt inducible kinase 2)

Beyond the preview

Go deeper on SIT-033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIT-033.

Explore the full profile